**Highlights of This Issue 4293**

**SPECIAL FEATURES**

**CCR Translations**

4295 "License to Kill" Reflects Joint Action of CD4 and CD8 T Cells
Cornelis J.M. Melief
See related article, p. 4508

**CCR Perspectives in Drug Approval**

4297 Developing Standards for Breakthrough Therapy Designation in Oncology
Sandra J. Horning, Daniel A. Haber, Wendy K.D. Selig, S. Percy Ivy, Samantha A. Roberts, Jeff D. Allen, Ellen V. Sigal, and Charles L. Sawyers
See related article, p. 4305

4305 Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?
James C. Yao, Funda Meric-Bernstam, J. Jack Lee, and S. Gail Eckhardt
See related article, p. 4297

**Molecular Pathways**

4309 Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy
Veronique Nogueira and Nissim Hay

**Reviews**

4315 Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology
Charles Ferté, Andrew D. Trister, Erich Huang, Brian M. Bot, Justin Guinney, Frederic Commio, Solveig Sieberts, Fabrice André, Benjamin Besse, Jean-Charles Soria, and Stephen H. Friend

4326 BRAF in Melanoma: Current Strategies and Future Directions
April K.S. Salama and Keith T. Flaherty
<table>
<thead>
<tr>
<th>Page</th>
<th>Article Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4383</td>
<td>Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth</td>
<td>Zhenyu Ji, Raj Kumarah, Michael Taylor, Anupchelvi Rajadurai, Alexander Marzuka-Alcalai, Y. Erin Chen, Ching-Ni Jenny Njauw, Keith Flaherty, Goran Jonsson, and Hensin Tsao</td>
</tr>
<tr>
<td>4392</td>
<td>Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition</td>
<td>Yuji Piao, Ji Liang, Lindsay Holmes, Verlene Henry, Erik Sulman, and John F. de Groot</td>
</tr>
<tr>
<td>4404</td>
<td>β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-TermFunctional Anergy</td>
<td>Jessica J. O’Konek, Shingo Kato, Satomi Takao, Liat Izihak, Zheng Xia, Peter Illarianov, Gurdyal S. Besra, Masaki Terabe, and Jay A. Berzofsky</td>
</tr>
<tr>
<td>4412</td>
<td>Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776</td>
<td>Carl G. Engelke, Leslie A. Parsels, Yushen Qian, Qiang Zhang, David Karnak, Jordan R. Robertson, Daria M. Tansk, Dongping Wei, Mary A. Davis, Joshua D. Parsels, Lili Zhao, Joel K. Greenson, Theodore S. Lawrence, Jonathan Maybaum, and Meredith A. Morgan</td>
</tr>
<tr>
<td>4422</td>
<td>Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recomination Repair</td>
<td>Dongping Wei, Leslie A. Parsels, David Karnak, Mary A. Davis, Joshua D. Parsels, Amanda C. Marsh, Lili Zhao, Jonathan Maybaum, Theodore S. Lawrence, Yi Sun, and Meredith A. Morgan</td>
</tr>
<tr>
<td>4446</td>
<td>Memantine Protects Rats Treated with Intrathecal Methotrexate from Developing Spatial Memory Deficits</td>
<td>Peter D. Cole, Veena Vijayanathan, Nafeza F. Ali, Mark E. Wagshul, Eric J. Tanenbaum, Jeremy Price, Vidhi Dalal, and Maria E. Gulinello</td>
</tr>
<tr>
<td>4455</td>
<td>A Novel Aldehyde Dehydrogenase-3 Activator (Aldea-99) Protects Submandibular Gland Function from Irradiation without Accelerating Tumor Growth</td>
<td>Nan Xiao, Hongbin Cao, Che-Hong Chen, Christina S. Kong, Rehan Ali, Cato Chan, Davud Sirjani, Edward Graves, Albert Koong, Amato Giaccia, Daria Mochly-Rosen, and Quynh-Thuy Le</td>
</tr>
<tr>
<td>4465</td>
<td>Nimbolide, a Limonoid Triterpene, Inhibits Growth of Human Colorectal Cancer Xenografts by Suppressing the Proinflammatory Microenvironment</td>
<td>Subash C. Gupta, Sahdeo Prasad, Dhanya R. Sethumadhan, Mangalam S. Nair, Yin-Yuan Mo, and Bharat R. Aggarwal</td>
</tr>
<tr>
<td>4477</td>
<td>Identification of Circulating MicroRNA Signatures for Breast Cancer Detection</td>
<td>Maurice Chan, Chiew Suan Liaw, Shen Mo Ji, Hwee Huang Tan, Chow Yin Wong, Aye Aye Thike, Puay Hoon Tan, Gay Hui Ho, and Ann Siew-Gek Lee</td>
</tr>
<tr>
<td>4488</td>
<td>Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjutant Therapy for Resected Mucosal Melanoma</td>
<td>Bin Lian, Lu Si, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Lili Mao, Siming Li, Yan Kong, Bixia Tang, and Jun Guo</td>
</tr>
<tr>
<td>4499</td>
<td>Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers</td>
<td>Laleh Amiri-Kordestani, Victoria Luchenko, Cody J. Peer, Kambiz Ghaforian, James Reynolds, Deb Draper, Robin Fye, Sue Woo, David Venzon, John Wright, Monica Skarulis, William D. Figg, Tito Fojo, Susan E. Bates, and Richard L. Piekarsz</td>
</tr>
</tbody>
</table>
Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4⁺ and CD8⁺ T-cell Epitopes: KIF20A-Specific CD4⁺ T-cell Immunity in Patients with Malignant Tumor

Yusuke Tomita, Akira Yuno, Hirotake Tsukamoto, Satoru Senju, Yasuhiro Kuroda, Masatoshi Hirayama, Atsushi Irie, Kenta Kawahara, Junji Yatsuda, Akinobu Hamada, Hirofumi Jono, Koji Yoshida, Takuya Tsunoda, Hirotsgu Kohrogi, Yoshihiro Yoshitake, Yusuke Nakamura, Masanori Shinohara, and Yasuharu Nishimura

See commentary, p. 4295

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y. Yeap, Lynette M. Sholl, Bruce E. Johnson, and Pasi A. Jänne

LETTER TO THE EDITOR

Oncolytic Virotherapy Trials—Letter

Akseli Hemminki, Minna Oksanen, and Maiju Merisalo-Soikkeli

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer


Correction: MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows Rad51 foci (red) in pancreatic cancer cells treated with gemcitabine and radiation. Nuclei are stained with DAPI (blue). For details, see the article by Engelke and colleagues on page 4412 of this issue.

The Journal of Clinical and Translational Research v www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on April 9, 2017. © 2013 American Association for Cancer Research.